PapersFlow Research Brief
IL-33, ST2, and ILC Pathways
Research Guide
What is IL-33, ST2, and ILC Pathways?
IL-33, ST2, and ILC pathways refer to the signaling axis where the alarmin cytokine IL-33 binds its receptor ST2 on innate lymphoid cells (ILCs) to drive type 2 immune responses, tissue homeostasis, and mucosal immunity.
This field encompasses 21,809 papers on innate lymphoid cells interacting with IL-33 via ST2 in type 2 immunity, allergic inflammation, and regulatory T cell modulation. "IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (2005) established IL-33 as an IL-1 family cytokine that signals through ST2 to promote Th2 cytokines. These pathways regulate mucosal immunity and contribute to inflammatory diseases through ILC activation.
Topic Hierarchy
Research Sub-Topics
IL-33 ST2 Signaling
This sub-topic dissects IL-33/ST2 receptor-ligand interactions, downstream signaling via MyD88-IRAK-TRAF6, and alarmin release mechanisms. Researchers map nuclear vs. secreted IL-33 functions and decoy receptor regulation.
ILC2 Biology
This sub-topic examines ILC2 development, transcription factors (GATA3, RORα), and tissue-resident plasticity. Researchers study IL-33-driven ILC2 activation, proliferation, and cytokine production in lung and gut mucosa.
IL-33 in Allergic Inflammation
This sub-topic investigates IL-33 contributions to asthma, atopic dermatitis, and anaphylaxis pathogenesis. Researchers validate IL-33 blockade efficacy in preclinical models and biomarker-stratified clinical trials.
ILC Regulation by IL-33
This sub-topic covers IL-33 orchestration of ILC1, ILC2, ILC3 homeostasis and activation states. Researchers explore ILC plasticity, cross-talk, and metabolic reprogramming in response to IL-33 gradients.
IL-33 in Tissue Homeostasis
This sub-topic studies IL-33 maintenance of epithelial integrity, stem cell function, and repair programs. Researchers elucidate protective roles in wound healing, hair follicle cycling, and metabolic tissues.
Why It Matters
IL-33/ST2 signaling on ILCs influences allergic inflammation and tissue repair in mucosal sites, with implications for diseases like atherosclerosis. "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" (Ridker et al., 2017) showed that canakinumab, targeting the IL-1β pathway related to IL-33/ST2, reduced recurrent cardiovascular events by 15% in 10,061 patients versus placebo, independent of lipid lowering. This demonstrates therapeutic potential in cardiovascular disease, where IL-33 modulates innate immunity and ILC-driven responses. The pathways also intersect with adaptive immunity, affecting regulatory T cells in chronic inflammation.
Reading Guide
Where to Start
"IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (Schmitz et al., 2005) because it provides the foundational description of IL-33 as a ST2 ligand inducing type 2 cytokines, essential for understanding ILC pathway basics.
Key Papers Explained
"IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (Schmitz et al., 2005) defines IL-33/ST2 signaling for Th2 responses, which connects to ILC activation in type 2 immunity as per the cluster description. "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" (Ridker et al., 2017) extends IL-1 family insights to clinical outcomes in inflammation, relevant to IL-33-driven ILC roles in disease. "The expanding universe of T-cell subsets: Th1, Th2 and more" (Mosmann and Sad, 1996) contextualizes Th2 differentiation that IL-33/ST2 amplifies via ILCs.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current work builds on IL-33/ST2 in ILCs for mucosal immunity and allergic inflammation, with clinical translation seen in atherosclerosis trials. The 21,809 papers emphasize regulatory T cell interplay, but no preprints from the last 6 months or news from the last 12 months suggest focus remains on established mechanisms in inflammatory diseases.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Antiinflammatory Therapy with Canakinumab for Atherosclerotic ... | 2017 | New England Journal of... | 8.6K | ✓ |
| 2 | Cleavage of GSDMD by inflammatory caspases determines pyroptot... | 2015 | Nature | 6.2K | ✕ |
| 3 | The Inflammasomes | 2010 | Cell | 5.3K | ✓ |
| 4 | The Orphan Nuclear Receptor RORγt Directs the Differentiation ... | 2006 | Cell | 5.0K | ✓ |
| 5 | Unravelling the pathogenesis of inflammatory bowel disease | 2007 | Nature | 4.3K | ✕ |
| 6 | Interleukin-10-deficient mice develop chronic enterocolitis | 1993 | Cell | 4.3K | ✕ |
| 7 | Multiple significance tests: the Bonferroni method | 1995 | BMJ | 3.7K | ✓ |
| 8 | The expanding universe of T-cell subsets: Th1, Th2 and more | 1996 | Immunology Today | 3.7K | ✕ |
| 9 | IL-33, an Interleukin-1-like Cytokine that Signals via the IL-... | 2005 | Immunity | 3.6K | ✓ |
| 10 | Interaction between microbiota and immunity in health and disease | 2020 | Cell Research | 3.6K | ✓ |
Frequently Asked Questions
What is the role of IL-33 and ST2 in type 2 immunity?
IL-33 acts as an alarmin cytokine that binds ST2 on innate lymphoid cells and T helper type 2 cells to induce type 2 cytokines like IL-4, IL-5, and IL-13. "IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (Schmitz et al., 2005) demonstrated that IL-33 signaling via ST2 drives Th2-associated responses critical for mucosal immunity.
How do ILCs interact with IL-33 in allergic inflammation?
Innate lymphoid cells (ILCs) express ST2 and respond to IL-33 by producing type 2 cytokines that amplify allergic inflammation. This pathway maintains tissue homeostasis but contributes to pathologies like asthma and atopic dermatitis through ILC activation. The cluster description notes ILCs regulate allergic inflammation via IL-33 interactions.
What is the connection between IL-33/ST2 and inflammatory diseases?
IL-33/ST2 signaling on ILCs promotes type 2 immunity that intersects with inflammatory conditions, including atherosclerosis. "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease" (Ridker et al., 2017) linked IL-1 family pathways, akin to IL-33, to reduced cardiovascular events. ILC pathways influence regulatory T cells in these diseases.
How does IL-33 signaling occur via ST2?
IL-33 binds the receptor ST2, an IL-1 receptor-related protein, forming a complex that activates NF-κB and MAP kinases to induce cytokine production. "IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (Schmitz et al., 2005) identified ST2 as the functional receptor for IL-33, driving Th2 responses.
What is the current state of research on IL-33, ST2, and ILC pathways?
Research includes 21,809 papers focusing on ILC roles in type 2 immunity and mucosal immunity via IL-33/ST2. Key works link these pathways to adaptive immunity and inflammatory diseases. No recent preprints or news coverage from the last 12 months indicate steady but non-accelerating interest.
Open Research Questions
- ? How do IL-33/ST2 signals on ILCs precisely modulate regulatory T cell function in mucosal tissues?
- ? What mechanisms link IL-33-driven ILC activation to chronic allergic inflammation versus protective type 2 immunity?
- ? In what ways do microbiota interactions influence IL-33/ST2 signaling in ILCs during inflammatory bowel disease?
- ? How does IL-33/ST2 pathway dysregulation contribute to cardiovascular events beyond IL-1β inhibition?
- ? What are the downstream effectors of ST2 signaling in ILCs that maintain tissue homeostasis?
Recent Trends
The field maintains 21,809 works with no specified 5-year growth rate, indicating stable research volume on IL-33/ST2/ILC roles in type 2 immunity.
Highly cited papers like "IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (Schmitz et al., 2005, 3636 citations) anchor signaling basics.
No recent preprints or news signal shifts, with emphasis on applications in atherosclerosis per Ridker et al. .
2017Research IL-33, ST2, and ILC Pathways with AI
PapersFlow provides specialized AI tools for Immunology and Microbiology researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching IL-33, ST2, and ILC Pathways with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Immunology and Microbiology researchers